Veeva Pulse Data Shows New Science Calls for More Connected Engagement
Synchronizing sales and marketing improves outcomes, yet 65% of field engagements are not SINGAPORE, Dec. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today released its latest Veeva Pulse Field Trends Report, showing connected sales and marketing engagement helps biopharmas balance healthcare professionals' (HCP) need for deep scientific information on complex medicines...
Former CSL CEO Paul Perreault appointed strategic adviser to Microbio
Establishing sepsis diagnostic InfectID™ as the new standard of care BRISBANE, Australia, Dec. 5, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has today announced the appointment of Paul Perreault as a strategic advisor. Mr Perreault is the former CEO of CSL and considered a pre-eminent global biotech leader. He was Chief Executive Officer...
LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications
NORWALK, Conn., Dec. 5, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will distribute Clariant's pharmaceutical-grade high-functional excipients – including their polyethylene glycols (PEGs) and...
CU Medicine invents a non-invasive technology for people with uninvestigated bowel symptoms
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- The Chinese University of Hong Kong's Faculty of Medicine (CU Medicine) has, for the first time, discovered novel microbial signatures associated with inflammation of the gastrointestinal (GI) tract and transformed such signatures into clinically applicable non-invasive tests for early diagnosis and timely intervention. This invention can effectively differentiate common chronic gut disorders...
Rhein Laser Announces FDA 510(k) Clearance of UroFiber 60Q
The Most Powerful Thulium SuperPulsed Fiber Laser for Urology is Here WUHAN, China, Dec. 4, 2024 /PRNewswire/ -- Rhein Laser Technologies Co., Ltd. is proud to announce that its UroFiber® 60Q SuperPulsed Thulium Fiber Laser System received FDA 510(k) clearance (K242293) on November 19, 2024, marking a significant breakthrough in surgical laser development. This certification makes Rhein Laser the first Chinese...
China NMPA approves Simcere’s Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Administration. This product is indicated for the improvement of neurological symptoms, daily activities, and functional impairment due to acute ischemic...
Akeso’s Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had progressed after prior PD-(L)1 inhibitor treatment, were presented at the 2024 Asian...
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter
AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to use an all-in-one high-density mapping and dual energy ablation catheter for the treatment of persistent atrial fibrillation and atrial flutter, heart arrhythmias that affect millions of people worldwide, after receiving approval...
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24. EVER001 was...
Exciting Offers Await at the 2024 Hong Kong Brands and Products Expo: Herbalgy Presents Exclusive Deals & Debuting “Yick Kee Balanced Tea Limited” Health Tea Bags!
Exclusive Discounts Up to 38% and Limited Edition Gifts HONG KONG, Dec. 4, 2024 /PRNewswire/ -- As December approaches, the highly anticipated Hong Kong Brands and Products Expo is just around the corner. Herbalgy Pharmaceutical Limited, a proud participant in this annual shopping event for many years, is excited to announce a...
